SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hester Biosciences informs about outcome of board meeting

09 May 2025 Evaluate
Hester Biosciences has informed that with reference to the letter dated 2 May 2025 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter and year ended 31 March 2025 and to consider the declaration of dividend, if any, on the equity shares of the Company for the financial year 2024-25, and pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors, in their Meeting held today, have approved the followings: Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2025, as recommended by Audit Committee and the Audited Standalone and Consolidated Financial Statements for the year ended 31 March 2025. Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended time to time), we hereby state that the Statutory Auditors of the Company, Chandulal M. Shah & Co., Chartered Accountants (FRN: 101698W) have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31 March 2025; Recommended dividend of ?7 (Seven) per equity share of ?10 each (70%) for the financial year 2024-25, subject to approval of members at the ensuing Annual General Meeting; and appointment of Shah & Shah Associates, Company Secretaries, Ahmedabad, as a Secretarial Auditors for a period of five consecutive years from FY 2025-26 to FY 2029-30, as recommended by Audit Committee, subject to approval of members at the ensuing annual general meeting. The details as required under Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 dated is enclosed.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences Share Price

1498.00 18.75 (1.27%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×